PLX
#3639
Protalix BioTherapeutics, Inc. Common Stock
2.3 7 USD
+0.03%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
+2.60%
Monthly Change
+2.16%
6 month change
-18.84%
Year Change
-18.84%
Previous Close
2.3 1
Open
2.3 6
Low
2.3 5
High
2.3 9
Volume
176
Financials
- Market Capitalization 190.95 M
- Employee 226
- Founded 1993
- CEO Dror Bashan
- Website www.protalix.com
- Headquarter Delaware, United States
- FIGI BBG000JW08N5
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-22.5
Price to sales ratio
2.68
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 3634 |  PRQR ProQR Therapeutics N.V. - Ordinary Shares | 1.83 USD | +7.02% | +3.98% | -0.54% | -5.18% | 192.81 M USD | ||
| 3638 |  IMUX Immunic, Inc. - Common Stock | 14.05 USD | -0.35% | +8.08% | -4.94% | +1514.94% | 191.38 M USD | ||
| 3643 |  NBP NovaBridge Biosciences - American Depositary Shares | 1.65 USD | +2.48% | -2.37% | -26.99% | -63.41% | 190.38 M USD | ||
| 3646 |  VYGR Voyager Therapeutics, Inc. - Common Stock | 3.13 USD | +4.33% | +3.64% | -17.41% | -32.69% | 189.12 M USD |
Frequently asked questions about Protalix BioTherapeutics, Inc. Common Stock
What is the Protalix BioTherapeutics, Inc. Common Stock stock price today?
The current price of Protalix BioTherapeutics, Inc. Common Stock (PLX) is 2.37. Over the past 24 hours, the stock has changed by +2.60%. Follow the PLX chart for real-time price dynamics.
What is the stock ticker of Protalix BioTherapeutics, Inc. Common Stock?
Protalix BioTherapeutics, Inc. Common Stock trades under the ticker PLX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Protalix BioTherapeutics, Inc. Common Stock stock going up?
PLX has changed by +0.42% over the last week, +2.16% over the last month, and -18.84% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Protalix BioTherapeutics, Inc. Common Stock?
Protalix BioTherapeutics, Inc. Common Stock currently has a market capitalization of 190.95 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Protalix BioTherapeutics, Inc. Common Stock earnings last quarter?
Last quarter, Protalix BioTherapeutics, Inc. Common Stock reported earnings of 0.23 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Protalix BioTherapeutics, Inc. Common Stock revenue for the last quarter?
Protalix BioTherapeutics, Inc. Common Stock reported quarterly revenue of 33.75 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Protalix BioTherapeutics, Inc. Common Stock net income for the last quarter?
Protalix BioTherapeutics, Inc. Common Stock reported net income of 18.32 M for the last quarter. The previous quarter showed -5.5 M, which means net income changed by +432.79%.
How many employees does Protalix BioTherapeutics, Inc. Common Stock have?
As of the latest available data, Protalix BioTherapeutics, Inc. Common Stock has 226 employees. Workforce size can provide additional context about the company's scale and operations.
What is Protalix BioTherapeutics, Inc. Common Stock EBITDA?
Protalix BioTherapeutics, Inc. Common Stock EBITDA is 21.55 M, and its EBITDA margin is 63.85%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Protalix BioTherapeutics, Inc. Common Stock stock?
You can buy Protalix BioTherapeutics, Inc. Common Stock (PLX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Protalix BioTherapeutics, Inc. Common Stock stock?
Investing in Protalix BioTherapeutics, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the PLX chart and related analysis on metatrader.com as part of your research.